Profile data is unavailable for this security.
About the company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
- Revenue in USD (TTM)0.00
- Net income in USD-921.62m
- Incorporated2020
- Employees159.00
- LocationSummit Therapeutics Inc601 Brickell Key Drive, Suite 1000MIAMI 33131United StatesUSA
- Phone+1 (305) 203-2034
- Fax+1 (302) 655-5049
- Websitehttps://www.smmttx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaxcyte Inc | 0.00 | -657.20m | 7.75bn | 414.00 | -- | 2.47 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 7.81bn | 18.60k | -- | 2.29 | 22.48 | 1.94 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.82bn | 218.00 | -- | 8.66 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 7.95bn | 498.00 | -- | -- | -- | 91.18 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 8.74bn | 711.00 | 40.48 | 15.08 | 33.77 | 8.01 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 9.03bn | 2.40k | -- | 17.78 | -- | 8.17 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 9.12bn | 116.00 | -- | 20.51 | -- | 1,222.61 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 9.32bn | 3.10k | 117.31 | 4.62 | 50.70 | 7.66 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.76bn | 528.00 | -- | 17.19 | -- | 14.53 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 10.89bn | 159.00 | -- | 56.65 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Exelixis Inc | 2.32bn | 782.57m | 11.09bn | 1.08k | 15.34 | 5.19 | 13.66 | 4.78 | 2.78 | 2.78 | 8.23 | 8.23 | 0.8011 | 3.80 | 8.40 | 2,154,249.00 | 27.02 | 13.68 | 31.41 | 15.65 | 96.39 | 96.33 | 33.73 | 20.55 | 3.50 | -- | 0.00 | 0.00 | 6.98 | 18.63 | 50.13 | 47.58 | -22.60 | -- |
| Medpace Holdings Inc | 2.53bn | 451.12m | 11.81bn | 5.90k | 27.21 | 25.65 | 24.64 | 4.67 | 15.29 | 15.29 | 85.67 | 16.22 | 1.24 | -- | 7.24 | 428,853.20 | 22.13 | 18.52 | 55.42 | 37.53 | 30.06 | 29.60 | 17.83 | 17.15 | -- | -- | 0.00 | 0.00 | 19.97 | 22.27 | 11.57 | 25.50 | 0.0102 | -- |
| Ionis Pharmaceuticals Inc | 966.96m | -256.34m | 13.25bn | 1.07k | -- | 21.32 | -- | 13.70 | -1.71 | -1.71 | 5.87 | 3.84 | 0.3163 | 0.6054 | 45.47 | 904,542.60 | -8.39 | -11.71 | -10.45 | -13.72 | 98.78 | 98.42 | -26.51 | -44.15 | 2.78 | -- | 0.7414 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 14.35bn | 12.00 | -- | 2,952.53 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
Data as of Feb 13 2026. Currency figures normalised to Summit Therapeutics Inc's reporting currency: US Dollar USD
10.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2025 | 33.72m | 4.53% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 10.20m | 1.37% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 8.92m | 1.20% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 6.36m | 0.86% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.22m | 0.84% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 4.43m | 0.60% |
| Geode Capital Management LLCas of 30 Sep 2025 | 3.13m | 0.42% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 1.75m | 0.24% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.39m | 0.19% |
| Pictet Asset Management SAas of 31 Dec 2025 | 1.38m | 0.19% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
